A real-world study on the clinicopathological profile, treatment outcomes and health-related quality of life, anxiety and depression among patients with desmoid tumor at two tertiary care centers in India

BackgroundThe medical management of DT comprises tyrosine kinase inhibitors (TKIs), hormonal agents, anti-inflammatory drugs with the recently approved gamma secretase inhibitor nirogacestat being the current standard of care. Real-world data on evolving treatment landscapes of DT remains scarce.Met...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ghazal Tansir, Aparna Sharma, Bivas Biswas, Suryadev Narayan Sah, Somnath Roy, S. V. S. Deo, Sandeep Agarwala, Shah Alam Khan, Sameer Bakhshi, Deepam Pushpam
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2024-10-01
Series:	Frontiers in Oncology
Assuntos:	Desmoid tumor tyrosine kinase inhibitors oral metronomic therapy quality of life rare diseases
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1382856/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!